WO2024201423 - MICROTUBULE-ASSOCIATED PROTEIN TAU TARGETING SIRNAS AND USES THEREOF

National phase entry is expected:
Publication Number WO/2024/201423
Publication Date 03.10.2024
International Application No. PCT/IB2024/053120
International Filing Date 29.03.2024
Title **
[English] MICROTUBULE-ASSOCIATED PROTEIN TAU TARGETING SIRNAS AND USES THEREOF
[French] ARNSI CIBLANT LA PROTÉINE TAU ASSOCIÉE AUX MICROTUBULES ET LEURS UTILISATIONS
Applicants **
BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
Inventors
RYU, Jin-Hyeob c/o BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
PARK, Young Jin c/o BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
PARK, Suhyeong c/o BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
LIM, Yu Na c/o BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
KIM, Insun c/o BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
KWON, Mincheol c/o BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
KIM, Jihye c/o BIORCHESTRA CO., LTD. 2F-216, Venture-dong, KRIBB, 125, Gwahak-ro Yuseong-gu Daejeon 34141, KR
Priority Data
63/493,244   30.03.2023   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing5392
EPO Filing, Examination91912
Japan Filing531
South Korea Filing575
USA Filing, Examination56135
MasterCard Visa

Total: 154545

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] The present disclosure relates to siRNA, which target MAPT transcript in a cell, leading to reduced expression of MAPT protein. Reduction of MAPT protein expression is beneficial for the treatment of certain medical disorders, e.g., a tauopathy.[French] La présente invention concerne un ARNsi qui cible un transcrit MAPT dans une cellule, conduisant à une expression réduite de la protéine MAPT. La réduction de l'expression de la protéine MAPT est bénéfique pour le traitement de certains troubles médicaux, par exemple, une tauopathie.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙